Editas Medicine, Inc.
EDIT · XNASCIK 1650664fmd_19WA5W3NV6RTGVAN2KT75Y70TMManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2014 to Sep 30, 2026, 48 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 6 | 14 | 32 | 21 | 91 | 26 | 20 | 78 | 32 | 41 |
| Research and development | 57 | 83 | 91 | 97 | 158 | 143 | 175 | 178 | 199 | 90 |
| Total operating expenses | 103 | 134 | 146 | 161 | 226 | 219 | 246 | 247 | 283 | 201 |
| Operating income | (97) | (120) | (114) | (141) | (135) | (193) | (226) | (169) | (251) | (160) |
| Interest expense | – | – | – | – | – | – | – | – | 0 | 2 |
| Other non-operating income (expense) | 0 | (0) | 4 | 7 | 19 | 1 | 6 | 16 | 14 | (0) |
| Income tax expense | – | – | – | – | – | 0 | 0 | 0 | 0 | 0 |
| Net income | (97) | (120) | (110) | (134) | (116) | (193) | (220) | (153) | (237) | (160) |
| Net income to common shareholders | (97) | (120) | (110) | (134) | (116) | (193) | (220) | – | – | – |